At least one-third of the world's population has been infected with the hepatitis B virus (HBV), and 400 million people are chronic carriers. In most populations, chronic HBV infection is the ...

Because of the shared modes of transmission, hepatitis B virus (HBV)/hepatitis C virus (HCV) coinfection is not uncommon in highly endemic areas and among subjects with a high risk of parenteral ...

Researchers at Oregon Health & Science University have developed the first transgenic nonhuman primate model—genetically ...

The American Gastroenterology Association (AGA) updated its clinical practice guidelines for managing hepatitis B reactivation (HBVr) in at-risk individuals, recommending antiviral prophylaxis for ...

GSK is prioritizing development of its hepatitis B treatment bepirovirsen as the pharma ends work on another potential ...

The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to brelovitug (BJT-778) for the treatment of chronic hepatitis delta (CHD).

New model predicts HCC risk in noncirrhotic chronic hepatitis B patients, improving early detection strategies.

Existing treatment criteria for chronic hepatitis B virus (HBV) infection are mainly based on data from observational studies, such as the REVEAL study from Taiwan, which was initiated in the early ...